Patient characteristics
| Clinical characteristic . | CHOP treated, no. (%), n = 82 . | R-CHOP treated, no. (%), n = 190 . |
|---|---|---|
| Age > 60 y | 41 (50) | 107 (56) |
| Male sex | 51 (63) | 128 (67) |
| PS > 1 | 30 (37) | 66 (35) |
| LDH > normal | 46 (56) | 90 (47) |
| Extranodal sites > 1 | 14 (17) | 39 (21) |
| Stage III/I | 45 (55) | 97 (51) |
| IPI score at diagnosis | ||
| 0 | 12 (15) | 26 (14) |
| 1, 2 | 32 (40) | 91 (48) |
| 3-5 | 37 (45) | 73 (38) |
| Pathology of biopsy | ||
| DLBCL | 82 (100) | 181 (95) |
| PMBCL | 9 (5) | |
| Site | ||
| Nodal | 70 (85) | 145 (76) |
| Extranodal | 12 (15) | 45 (24) |
| Relapse or progression | 38 (46) | 55 (29) |
| Clinical characteristic . | CHOP treated, no. (%), n = 82 . | R-CHOP treated, no. (%), n = 190 . |
|---|---|---|
| Age > 60 y | 41 (50) | 107 (56) |
| Male sex | 51 (63) | 128 (67) |
| PS > 1 | 30 (37) | 66 (35) |
| LDH > normal | 46 (56) | 90 (47) |
| Extranodal sites > 1 | 14 (17) | 39 (21) |
| Stage III/I | 45 (55) | 97 (51) |
| IPI score at diagnosis | ||
| 0 | 12 (15) | 26 (14) |
| 1, 2 | 32 (40) | 91 (48) |
| 3-5 | 37 (45) | 73 (38) |
| Pathology of biopsy | ||
| DLBCL | 82 (100) | 181 (95) |
| PMBCL | 9 (5) | |
| Site | ||
| Nodal | 70 (85) | 145 (76) |
| Extranodal | 12 (15) | 45 (24) |
| Relapse or progression | 38 (46) | 55 (29) |
PS indicates Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; DLBCL, diffuse large B-cell lymphoma; and PMBCL, primary mediastinal B-cell lymphoma.